Browse studies

Find your next paid study

3,218 recruiting studies matching your filters

Mitigation Efforts in Arsenic Exposure With Folic Acid Supplementation: Reducing Toxicity and Exploring the Impact on Lung Health

The purpose of this study is to evaluate the effects on folic acid supplementation in a population living in an environment with chronic arsenic exposure in Bi…

Arsenic and/or Arsenic Compound Adverse Reaction

Estimated

~$10 – $750

Actual pay is set by the research site.

University of Alabama at BirminghamNCT05656664

Phase 1

A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors

This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effec…

Advanced Solid Tumor

Estimated

~$150 – $4,200

Actual pay is set by the research site.

ParVation Therapeutics, Inc.NCT06220864

Phase 1

A Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients With Advanced Solid Tumors as a Monotherapy or in Combination With Pembrolizumab

Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 De…

Advanced Solid Tumor

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Strand Therapeutics Inc.NCT06249048

Phase 3

A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors

This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approxima…

Advanced Gastrointestinal Stromal TumorsMetastatic Cancer

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Cogent Biosciences, Inc.NCT05208047

Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors

SURVIVORS Study participants are being asked to take part in this research study called HODNIRS because the participant is a survivor of Hodgkin Lymphoma (HL)…

Hodgkin Lymphoma, Adult

Estimated

~$10 – $750

Actual pay is set by the research site.

St. Jude Children's Research HospitalNCT06421987

Phase 1

Pilot Trial of the IL-4 Receptor Antagonist Dupilumab Plus Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

Pilot trial of the IL-4 receptor antagonist dupilumab plus pembrolizumab, paclitaxel, and carboplatin in locally advanced triple negative breast cancer (TNBC).…

Locally Advanced Triple Negative Breast CancerTNBC - Triple-Negative Breast Cancer

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Rima PatelNCT06637306

Phase 3

An Open-Label Study to Evaluate Safety of Pitolisant in Participants With Prader-Willi Syndrome

The purpose of this study is to assess safety of pitolisant in eligible participants with Prader-Willi syndrome (PWS) who completed the End of Treatment (EOT) …

Prader-Willi Syndrome

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Harmony Biosciences Management, Inc.NCT07219485

Phase 2

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-aller…

Drug AllergyCephalosporin AllergyDrug Hypersensitivity+4 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Massachusetts General HospitalNCT06406114

Observational

iKinnect Mobile Technology to Reduce Teen Substance Misuse and Health Disparities

The goal of this study is to test the newly expanded WisePath for Teens (WPT) for substance use app, a direct-to-consumer paired mobile phone app for iOS and A…

Substance UseSubstance AbuseSuicide+1 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Evidence-Based Practice Institute, Seattle, WANCT05897164

Phase 1

PHASE 1, OPEN-LABEL, FIRST-IN-HUMAN TRIAL OF INTRAPERITONEA L Lm-LLO-TT AND GEMCITABINE IN PARTICIPANTS WITH UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA

ClinicalTrials.gov Brief Summary This Phase 1, open-label, first-in-human study is designed to evaluate the safety, tolerability, and recommended dose of intr…

Pancreas Cancer, Duct Cell AdenocarcinomaPancreatic CancerAdvanced Pancreatic Adenocarcinoma

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Loki Therapeutics, Inc.NCT07828236

Phase 1

Phase 1b/2 Trial of Pidnarulex in MYC Aberrant Lymphoma

This phase Ib/II trial tests the safety, side effects, best dose and how well giving CX-5461 works for the treatment of patients with B-cell non-Hodgkin lympho…

Burkitt LymphomaDouble-Expressor LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT07069699

Phase 2

A Randomized, Window of Opportunity Trial of Tirzepatide in Women With Obesity and a Diagnosis of Endometrial Intra-epithelial Neoplasia (EIN) or Grade 1 Endometrial Cancer

The goal of this study is to determine the anti-proliferative effect of tirzepatide on the endometrium of patients with endometrial intra-epithelial neoplasia …

Endometrial CancerEndometrial Intraepithelial NeoplasiaGrade 1 Endometrial Endometrioid Carcinoma

Estimated

~$75 – $2,000

Actual pay is set by the research site.

UNC Lineberger Comprehensive Cancer CenterNCT07078838